KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants

BMC Cancer

Sabine Heublein⁴  Katinka Grasse¹  Harald Hessel¹  Alexander Burges²  Miriam Lenhard²  Jutta Engel³  Thomas Kirchner¹  Udo Jeschke⁴  Doris Mayr¹ 

[1] Department of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany

[2] Department of Gynecology and Obstetrics, Ludwig-Maximilians-University of Munich-Campus Grosshadern, Munich, Germany

[3] Department of Biostatistics and Epidemiology, Munich Tumor Registry, Ludwig-Maximilians-University of Munich, Munich, Germany

[4] Department of Gynecology and Obstetrics, Ludwig-Maximilians-University of Munich-Campus Innenstadt, Munich, Germany

关键词: Implants;    Serous ovarian borderline tumor;    BRAF;    KRAS;   

Others  :  1079510
DOI  :  10.1186/1471-2407-13-483

 received in 2013-07-10, accepted in 2013-09-26,  发布年份 2013

【 摘 要 】

Background

Patients diagnosed for a serous ovarian borderline tumor (s-BOT) typically present with an excellent clinical outcome. However there have been controversies concerning the prognostic impact of so-called implants, an extra ovarian spread occurring alongside the s-BOT in certain cases. It remains obscure whether these implants actually resemble metastasis owning the same genetic pattern as the ovarian primary or whether they develop independently.

Methods

The current study, in the aim of further clarifying the genetic origin of implants, assessed BRAF/KRAS hot spot mutations and the p53/p16^INK4a immunophenotype of s-BOTs and corresponding implants (n = 49) of 15 patients by pyro-sequencing and immunostaining, respectively.

Results

A significant proportion of both s-BOTs and implants showed KRAS or BRAF mutation and though p16^INK4a was found to be abundantly expressed, p53 immunoreactivity was rather low. When genotypes of BRAF/KRAS mutated s-BOTs and corresponding implants were compared no patient presented with a fully matching mutation profile of s-BOTs and all corresponding implants.

Conclusions

The current study reveals genetic heterogeneity of s-BOTs and implants, as none of the markers examined showed constant reciprocity. Hence, our findings may assist to explain the different clinical presentation of s-BOTs and implants and might encourage to applying more individualized follow up protocols.

【 授权许可】

   
2013 Heublein et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]McCluggage WG: The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol 2010, 22(5):462-472.
• [2]Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG: Grading ovarian serous carcinoma using a two-tier system. Am j surg pathol 2004, 28(4):496-504.
• [3]Lenhard MS, Mitterer S, Kumper C, Stieber P, Mayr D, Ditsch N, Friese K, Burges A: Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol 2009, 145(2):189-194.
• [4]Silva EG, Gershenson DM, Malpica A, Deavers M: The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 2006, 30(11):1367-1371.
• [5]Kurman RJ, Seidman JD, Shih IM: Serous borderline tumours of the ovary. Histopathology 2005, 47(3):310-315.
• [6]Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C: Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 1998, 83(10):2157-2163.
• [7]Seidman JD, Kurman RJ: Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000, 31(5):539-557.
• [8]Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P, Pomel C, Cote JF, Haie-Meder C, Duvillard P, et al.: Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol Off J Eur Soc Med Oncol / ESMO 2003, 14(4):592-598.
• [9]Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR: Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 2005, 29(6):707-723.
• [10]Tavassoli FA, Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
• [11]Mayr D, Hirschmann A, Lohrs U, Diebold J: KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006, 103(3):883-887.
• [12]McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al.: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773(8):1263-1284.
• [13]Radojicic J, Zaravinos A, Spandidos DA: HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis. Int J Biol Markers 2012, 27(1):1-12.
• [14]Lee KE, Bar-Sagi D: Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 2010, 18(5):448-458.
• [15]Slattery ML, Wolff RK, Herrick J, Caan BJ, Samowitz W: Tumor markers and rectal cancer: support for an inflammation-related pathway. Int J Cancer J Int Du Cancer 2009, 125(7):1698-1704.
• [16]Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA: Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994, 54(11):2914-2918.
• [17]Soussi T: p53 alterations in human cancer: more questions than answers. Oncogene 2007, 26(15):2145-2156.
• [18]Zong L, Chen P, Xu Y: Correlation between P53 expression and malignant risk of gastrointestinal stromal tumors: evidence from 9 studies. Eur J Surg Oncol J Eur Soc Surg Oncol British Assoc Surg Oncol 2012, 38(3):189-195.
• [19]Figarella Branger D, Maues De Paula A, Colin C, Bouvier C: Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Revue Neurol 2011, 167(10):683-690.
• [20]Vereczkey I, Serester O, Dobos J, Gallai M, Szakacs O, Szentirmay Z, Toth E: Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol Oncol Res 2011, 17(3):551-559.
• [21]Ziolkowska-Seta I, Madry R, Kraszewska E, Szymanska T, Timorek A, Rembiszewska A, Kupryjanczyk J: TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol 2009, 112(1):179-184.
• [22]Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer res 1991, 51(11):2979-2984.
• [23]Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Borresen-Dale AL, Overgaard J: A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008, 47(4):600-607.
• [24]O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005, 29(8):1034-1041.
• [25]Brustmann H: Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 2007, 26(2):147-153.
• [26]Giurgea LN, Ungureanu C, Mihailovici MS: The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom J Morphol Embryol Revue Roumaine De Morphol Et Embryol 2012, 53(4):967-973.
• [27]Remmele W, Stegner HE: [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987, 8(3):138-140.
• [28]Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, et al.: The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial. Int J Cancer J Int Du Cancer 2012, 131(4):980-986.
• [29]Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009, 205(12):858-862.
• [30]Pothuri B, Leitao M, Barakat R, et al.: Genetic Analysis of Ovarian Carcinoma Histogenesis. 2001. [Abstract in Society of Gynecologic Oncologists, 32nd Annual Meeting]
• [31]Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, et al.: Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007, 31(2):161-169.
• [32]Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M: Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004, 64(19):6915-6918.
• [33]Cheng EJ, Kurman RJ, Wang M, Oldt R, Wang BG, Berman DM, Shih Ie M: Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 2004, 84(6):778-784.
• [34]Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih Ie M: Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 2012, 226(3):413-420.
• [35]Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164(5):1511-1518.
• [36]Thomas NA, Neville PJ, Baxter SW, Campbell IG: Genetic analysis of benign ovarian tumors. Int J Cancer J Int Du Cancer 2003, 105(4):499-505.
• [37]Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM: BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 2010, 177(4):1611-1617.
• [38]Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, Giessen C, Haas M, Aubele P, Schulz C, Boeck S, et al.: Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anti-cancer Drugs 2011, 22(9):913-918.
• [39]Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, Kirchner T: Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol Off J United States Can Acad Pathol Inc 2011, 24(7):1015-1022.
• [40]Yachida S, Mudali S, Martin SA, Montgomery EA, Iacobuzio-Donahue CA: Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol 2009, 33(12):1823-1832.
• [41]Marchoudi N, Amrani Hassani Joutei H, Jouali F, Fekkak J, Rhaissi H: Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie-biologie 2013.
• [42]Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K: KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. British J Cancer 2008, 99(12):2020-2028.
• [43]Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, et al.: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004, 202(3):336-340.
• [44]Emerson RE, Wang M, Liu F, Lawrence WD, Abdul-Karim FW, Cheng L: Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 2007, 26(4):387-394.
• [45]Gu J, Roth LM, Younger C, Michael H, Abdul-Karim FW, Zhang S, Ulbright TM, Eble JN, Cheng L: Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001, 93(15):1147-1152.
• [46]Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC Jr: Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992, 84(23):1793-1798.
• [47]Khalique L, Ayhan A, Whittaker JC, Singh N, Jacobs IJ, Gayther SA, Ramus SJ: The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer J Int Du Cancer 2009, 124(7):1579-1586.
• [48]Kupryjanczyk J, Thor AD, Beauchamp R, Poremba C, Scully RE, Yandell DW: Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol Off J United States Can Acad Pathol Inc 1996, 9(3):166-173.
• [49]Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC: Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998, 58(11):2328-2330.